Abstract: Antigens and vaccines containing purified oligomers (1-50 units) of the repeating pentasaccharide unit of type III Group B Stretococcus (III GBS) polysaccharide capsule. Methods of making the antigen by recovering polysaccharide from cultured III GBS or medium and digesting the polysaccharide with a specific endo-.beta.-galactosidase. Enzymatic cleavage of bacterial polysaccharide to make purified oligomers. A purified trypsin-resistant C surface protein, m.w. about 14,000 and vaccine. Passive immunization using the above vaccines. Immunoassays for GBS immunodeterminants or anti-GBS antibodies.
Type:
Grant
Filed:
November 24, 1992
Date of Patent:
April 12, 1994
Assignee:
Brigham and Women's Hospital, Inc.
Inventors:
Dennis L. Kasper, Harold J. Jennings, Nancy J. Levy, Michael R. Wessels
Abstract: Compounds of the formulae, ##STR1## are provided where L is a linking group of the formula, ##STR2## is --Sn(n--C.sub.4 H.sub.9).sub.3 or --Sn(CH.sub.3).sub.3, HgCl or --N.sub.2.sup.+ ; R is hydrogen, methyl, mono-, di- or oligosaccharide; and R' is methyl. The compounds are site-specifically halogenated or radiohalogenated at the A group and coupled with macromolecules such as monoclonal antibodies, peptides or other proteins.
Abstract: The present invention is directed to novel THC derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the THC metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
Abstract: A new series of bifunctional chelating agents useful for attaching metal ions to proteins, polypeptides and other polymers and methods for their preparation are described. These reagents are unique in their ability to bind a variety of metal ions and to yield a high metal ion concentration per protein molecule. Using these methods polymeric analogs of these bifunctional chelating agents called Starburst ligands can also be obtained. Protein metal chelates thus obtained will have useful radiophysical, chemical, fluorescent, photochemical and magnetic properties suitable for biomedical applications.
Abstract: A protein conjugate or mixture useful in immunotherapy composed of a biological response modifier (BRM) and an allergen is disclosed. In use the protein conjugate or mixture is combined with a pharmaceutically acceptable carrier. Cytokines, bacterial, fungal and viral immunopotentiators and thymus hormones are disclosed as suitable BRM's for use in the invention.
Abstract: The present invention has multiple aspects. In its first aspect the present invention is directed to a trifunctional antibody-like compound that has tissue, organ, cell or molecule specificity and which is capable of being bifunctional when immobilized, via binding, at the tissue, organ, cell or molecule for which it has specificity. In particular, the present invention is directed to a trifunctional antibody-like compound of Formula I:F.sub.1 ab'--L--F.sub.2 ab'--L--F.sub.3 ab' (1)wherein L is the same or two different moieties for cross-linking F.sub.1 ab', F.sub.2 ab' and F.sub.3 ab';wherein F.sub.1 ab' is an Fab'-like fragment of a polyclonal or monoclonal antibody having specificity for an antigen expressed by the organ, tissue, cell or molecule of interest;wherein F.sub.2 ab' is an Fab'-like fragment of a polyclonal or monoclonal antibody having the same specificity as F.sub.
Abstract: An immunogenic composition for raising antisera to a drug comprising immunologically active carrier protein to which is bound at least two types of hapten, each hapten comprising a drug molecule and, optionally, a bridging group, a method of raising antisera to a drug using said immunogenic composition, and a method of alleviating an overdose of a tricyclic depressant drug comprising an effective amount of antisera raised to an immunogen.
Abstract: DNA encoding glycoproteins gD, gI and part of gE from Marek's disease herpesvirus is described. The DNA is useful for probes to detect the DNA in the herpesvirus, for expression to produce the glycoproteins can be used for producing the antibodies which specifically recognize the three glycoprotein antigens, and in the case of the latter two genes, for potential insertion sites for foreign genes. Novel glycoproteins and regulatory sequences are also disclosed.
Type:
Grant
Filed:
March 9, 1992
Date of Patent:
October 12, 1993
Assignee:
Board of Trustees operating Michigan State University
Inventors:
Leland F. Velicer, Peter Brunovskis, Paul M. Coussens
Abstract: DNA encoding glycoproteins gD, gI and part of gE from Marek's disease herpesvirus is described. The DNA is useful for probes to detect the DNA in the herpesvirus, for expression to produce the glycoproteins can be used for producing the antibodies which specifically recognize the three glycoprotein antigens, and in the case of the latter two genes, for potential insertion sites for foreign genes. Novel glycoproteins and regulatory sequences are also disclosed.
Type:
Grant
Filed:
March 4, 1992
Date of Patent:
October 12, 1993
Assignee:
Board of Trustees operating Michigan State University
Inventors:
Leland F. Velicer, Peter Brunovskis, Paul M. Coussens
Abstract: A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.
Abstract: New polysubstituted diethylenetriaminepentaacetic acid chelates and protein conjugates of the same are described together with the methods of preparing such compounds. A method of delivering radiolabelled compound of the present invention to a target site while minimizing the distribution of the compound to non-targeted organs or tissues is also disclosed.
Type:
Grant
Filed:
August 22, 1991
Date of Patent:
September 21, 1993
Assignee:
The United States of America as represented by the Secretary of Health and Human Services
Abstract: Multiple antigen peptide systems are described in which a large number of antigens are bound to the functional groups of a dendritic core molecule providing a high concentration of antigen in a low molecular volume. The products are useful for producing chemically defined univalent or multivalent vaccines and in diagnostic tests.
Abstract: Ligand reagents are disclosed which consist essentially of recombinant hyperglycosylated cytokines, expressed in yeast, which are purified and conjugated to various functional moieties, for example, biotin groups, via oligosaccharide residues.
Abstract: The present invention relates to antitumor compounds of the formula I: ##STR1## wherein M is selected from the group consisting of an hydrogen atom, a peptide residue, and a protein residue linked to the carbon atom via the amino residue of .epsilon.-lysine present therein which can be an antibody used to target the anti-tumor agent to the malignant cells, and R can be an antitumor agent such as daunorubicin, doxorubicin, or an epirublicin derivative.
Abstract: A method of selectively modifying an immunoglobulin having at least one Fab region and at least one Fc region, each region having an isoelectric point wherein said isoelectric point of the Fab fragment of said immunoglobulin is different than the isoelectric point of the Fc fragment of the immunoglobulin, said method comprising modification of the immunoglobulin at a pH between the respective isoelectric points of the Fab and Fc fragments of the immunoglobulin.
Type:
Grant
Filed:
November 14, 1990
Date of Patent:
May 4, 1993
Assignee:
University of Pittsburgh
Inventors:
Girish Ranadive, Howard S. Rosenzweig, Michael Epperly, William Bloomer
Abstract: Vi capsular polysaccharides conjugated to toxin-dependent proteins can be used to enhance antibody response and to convert T-dependent properties to the Vi capsular polysaccharide. A heterobifunctional crosslinking agent can be used to bind thiol derivatives of the Vi capsular polysaccharides to the proteins, such as diphtheria, tetanus toxoids, cholera toxin and Haemophilus influenzae.
Type:
Grant
Filed:
February 16, 1988
Date of Patent:
April 20, 1993
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Shousun C. Szu, Rachel Schneerson, John B. Robbins
Abstract: The invention relates to a DNA fragment containing at the most 315 pairs of nucleotides coding for a peptide which can be recognized by antibodies acting both against the "C" and "D" particles of the same poliovirus and against the VP-1 structural polypeptide of the capsid of this poliovirus. This peptide contains in particular the following sequence:Asp Asn Pro Ala Ser thr Thr Asn Lys Asp Lys Leu.
Abstract: The synthetic peptide TT3, the amino acid sequence of which corresponds to the region 947-967 of the tetanus toxin is recognized by different human Th cell clones in association with a wide range of alleles of the human major histocompatibility complex (MHC). Said peptide contains at least two epitopes, of which one (953-967) is recognized by the DR5-restricted clones and the other (947-960) is recognized by all other DR and DP alleles restricted clones. The TT3 peptide and the peptide corresponding to the 947-960 epitope can be used as universal carriers in the preparation of immunogenic conjugates consisting of at least one of said peptides and a natural or synthetic hapten derived from a pathogenic agent of interest.The immunogenic conjugates are particularly suitable for preparing synthetic vaccines able to provide a protective immunity against different pathogenic agents which is not genetically restricted or is only slightly genetically restricted.
Abstract: Modified antibodies are disclosed which have been modified by chemical conjugation with a heterobifunctional reagent, such as SPDP. The use of these modified antibodies in the diagnosis and therapy of cancer and other mammalian disease is also disclosed. Diagnostic uses include immunoscintography. The modified antibodies may be further conjugated with labels or biologically active molecules for use in such diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes.
Abstract: The present invention provides cross-linked protein compositions consisting of two or more units of a target-specific protein joined by binding sulfhydryl groups on the target-specific protein units to a sulfhydryl-selective cross-linking agent and a method of making the compositions. These cross-linked protein compositions combine an increase in binding affinity due to the presence of multiple identical binding sites and stability to reduction conditions.
Type:
Grant
Filed:
April 9, 1990
Date of Patent:
February 9, 1993
Assignee:
Centocor, Inc.
Inventors:
Richard T. Dean, John Lister-James, Raymond H. Boutin